KRAS and non-small cell lung carcinoma: In this rapidly evolving scenario, we sought to investigate the correlation between KRAS G12C dynamic variations and treatment outcomes in a cohort of patients with advanced NSCLC who were receiving targeted therapy with sotorasib in a real‐world clinical setting.